RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
$14.50
arrow_downward
-1.83%(-0.27) 1D
$14.49
arrow_downward
-0.07% (-0.010)bedtimeAfter hours
Closed: Sep 25, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RARE...
Open
$14.87
High
$14.94
Low
$14.15
Mkt. cap
1.43B
Avg. vol.
5.21M
Volume
4.31M
52-wk high
$39.89
52-wk low
$12.73
EPS
-$5.84
Beta
0.32
Shares outstanding
98.59M
No. of employees
1K
Open
$14.87
High
$14.94
Low
$14.15
Mkt. cap
1.43B
Avg. vol.
5.21M
Volume
4.31M
52-wk high
$39.89
52-wk low
$12.73
EPS
-$5.84
Beta
0.32
Shares outstanding
98.59M
No. of employees
1K
News stories
From web sources and news partners
MarketBeat
·
18 hours ago
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analysts
Investing.com
·
1 day ago
H.C. Wainwright reiterates Ultragenyx stock rating on FDA approval
Reuters
·
1 week ago
Ultragenyx sets $3.95 million price for rare disease gene therapy
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees1.37K
Founded2010
HeadquartersNovato, California, United States
SectorBiotechnology
Websiteultragenyx.com